Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 17/20 | 0.71 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.66 |
| ▸ | HDAC4 | P56524 | 4/20 | 0.66 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.66 |
| ▸ | HDAC7 | Q8WUI4 | 4/20 | 0.66 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.66 |
| ▸ | HDAC10 | Q969S8 | 4/20 | 0.66 |
| ▸ | HDAC11 | Q96DB2 | 4/20 | 0.66 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.66 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.66 |
| ▸ | HDAC9 | Q9UKV0 | 4/20 | 0.66 |
| ▸ | HDAC5 | Q9UQL6 | 4/20 | 0.66 |
| ▸ | KDR | P35968 | 3/20 | 0.66 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.66 |
| ▸ | CSF1R | P07333 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4766203 | 1.00 | EGFR (0.71) | EGFRHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL4764025 | 0.85 | EGFR (0.81) | EGFRHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL5437779 | 0.85 | EGFR (0.76) | EGFRHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL4772771 | 0.85 | EGFR (0.76) | EGFRHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL4774332 | 0.83 | EGFR (0.70) | EGFRHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL4773783 | 0.83 | EGFR (0.70) | EGFRHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL4764785 | 0.83 | EGFR (0.83) | EGFRHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL27603011 | 0.83 | EGFR (0.72) | EGFRHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL4772754 | 0.83 | EGFR (0.72) | EGFRHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL4764790 | 0.83 | EGFR (0.83) | EGFRHDAC3HDAC4HDAC1HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0938486-B1 | SUBSTITUTED PYRROLOPYRIMIDINES AND PROCESSES FOR THEIR PREPARATION | NOVARTIS AG (CH) | 2008-01-16 | — | — | EP | claimed |
| US-6180636-B1 | USED TO INHIBIT THE TYROSINE KINASE ACTIVITY OF THE RECEPTOR FOR THE EPIDERMAL GROWTH FACTOR AND C-ERBB2 KINASE AND CAN BE USED AS ANTITUMOR AGENTS | NOVARTIS AG (CH) | 2001-01-30 | — | — | US | claimed |
| EP-0938486-A1 | SUBSTITUTED PYRROLOPYRIMIDINES AND PROCESSES FOR THEIR PREPARATION | Novartis AG (CH) | 1999-09-01 | — | — | EP | claimed |
| WO-1998007726-A1 | SUBSTITUTED PYRROLOPYRIMIDINES AND PROCESSES FOR THEIR PREPARATION | NOVARTIS AG (CH) | 1998-02-26 | — | — | WO | claimed |
| EP-0938486-B1 | SUBSTITUTED PYRROLOPYRIMIDINES AND PROCESSES FOR THEIR PREPARATION | NOVARTIS AG (CH) | 2008-01-16 | — | — | EP | disclosed |
| US-6180636-B1 | USED TO INHIBIT THE TYROSINE KINASE ACTIVITY OF THE RECEPTOR FOR THE EPIDERMAL GROWTH FACTOR AND C-ERBB2 KINASE AND CAN BE USED AS ANTITUMOR AGENTS | NOVARTIS AG (CH) | 2001-01-30 | — | — | US | disclosed |
| EP-0938486-A1 | SUBSTITUTED PYRROLOPYRIMIDINES AND PROCESSES FOR THEIR PREPARATION | Novartis AG (CH) | 1999-09-01 | — | — | EP | disclosed |
| WO-1998007726-A1 | SUBSTITUTED PYRROLOPYRIMIDINES AND PROCESSES FOR THEIR PREPARATION | NOVARTIS AG (CH) | 1998-02-26 | — | — | WO | disclosed |